U.S. preclinical CRO Absorption Systems has signed a deal with Indian consulting firm Synerzys Lifecare, looking to pitch its testing services to the nation's growing generics market.
Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.
As more and more drugmakers eye antibody-drug conjugate development as a path to blockbusters, Catalent has licensed ADC technology from Redwood Bioscience, planning to roll the offering into its service platform.
InVentiv Health is betting on a big expansion in Japanese R&D, forming a strategic alliance with local CRO Bell Medical Solutions to offer lab services in the country.
Bristol-Myers Squibb has inked a preferred provider deal with Quintiles, selecting the CRO giant to handle global central lab services for its pipeline treatments.
After keeping its mid-stage data for a closely-watched and controversial drug for Duchenne muscular dystrophy under wraps, GlaxoSmithKline has pulled back part of the covers to reveal that drisapersen did in fact hit the primary endpoint on walking distance.
San Diego-based Ambrx welcomed an influx of cash for the further development of its drug-delivery technology: antibody drug conjugates, or ADCs.
The two groups have been working together for the past decade, helping build the city-state's reputation for R&D.
Device, diagnostics and drug companies should be working together and sharing intellectual property at a much sooner point in their research, argues Dr. Andrew von Eschenbach, who ran the FDA from 2005 to 2009.
Roche has stepped up with a $392 million deal designed to marry its work on new technology for delivering brain treatments with Isis' antisense programs for Huntington's disease. In the deal, the latest in a lengthy string for the Carlsbad, CA-based biotech company, Isis gains $30 million upfront with the rest payable on promised milestones.